Akèy › Timè nan sèvo › Texas
Etid klinik pou Timè nan sèvo nan Texas
42 etid pou Timè nan sèvo ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
- Baylor St. Luke's Medical Center, Houston
Ap rekriteFaz 1
Laj 21 a 70 · Tout sèks · Mizajou Sep 30, 2026 · NCT06815432Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
- Mays Cancer Center, UT Health San Antonio, San Antonio
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07470606Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
- The University of Texas M. D. Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07053033A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05048212Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0085, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07492680OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07655583Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- UT Southwestern Medical Center/Harold C Simmons Comprehensive Cancer Center, Dallas
- Cook Children's Medical Center, Fort Worth
- Texas Children's Hospital, Houston
Ap rekriteFaz 2
59 Months · Tout sèks · Mizajou Sep 15, 2026 · NCT05535166Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
- M D Anderson Cancer Center, Houston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT04988009Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05386108A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers
- MD Anderson Cancer Center, Houston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07467109A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NEXT Oncology - Austin, Austin
- Mary Crowley Cancer Research, Dallas
- MD Anderson Cancer Center - University of Texas, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06253871A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- UT MD Anderson Cancer Center, Houston
- UT Health San Antonio Mays Cancer Center, San Antonio
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT07428616Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
Ap rekriteEtid obsèvasyon
12 Months – 39 Years · Tout sèks · Mizajou Sep 8, 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
36 Months – 22 Years · Tout sèks · Mizajou Sep 4, 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 1, 2026 · NCT06161974A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- MD Anderson Cancer Center, Houston
- Community Clinical Trials, Kingwood
- Tranquil Clinical Research, Webster
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06764940A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
- Mary Crowley Cancer Research, Dallas
- The University of Texas M.D. Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06136884Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
- Ut Southwestern Medical Center, Dallas
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07139990Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection
- Houston Methodist Neal Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT07383649Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT07733674C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
12 Months – 25 Years · Tout sèks · Mizajou Aug 3, 2026 · NCT04099797Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- UT Southwestern Simmons Cancer Center, Dallas
- Baylor St. Luke's Medical Center | Baylor College of Medicine, Houston
- Houston Methodist Hospital, Houston
- ak 2 plis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jul 22, 2026 · NCT04427384Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT03830151A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 16, 2026 · NCT05673928Mapping of Human Cognition
- The University of Texas Health Science Center at Houston, Houston
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Jul 14, 2026 · NCT05989893Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
Ap rekriteFaz 2
12 Months – 39 Years · Tout sèks · Mizajou May 29, 2026 · NCT05843253A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
- M D Anderson Cancer Center, Houston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT05342454Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
- M D Anderson Cancer Center, Houston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 20, 2026 · NCT02754544Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT05064280EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
- The University of Texas MD Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 15, 2026 · NCT06649058Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT06810544The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Md Anderson Cancer Center, Houston
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 5, 2026 · NCT04075305Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
- M D Anderson Cancer Center, Houston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 5, 2026 · NCT05700721cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Elligo Health Research, Inc., Austin
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 ak plis · Tout sèks · Mizajou Jan 20, 2026 · NCT05366881Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors
- MD Anderson Cancer Center, Houston
Ap rekrite
Laj 15 a 39 · Tout sèks · Mizajou Jan 9, 2026 · NCT06799481S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- UT Southwestern Clinical Center at Richardson/Plano, Richardson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 8, 2025 · NCT03418961Systematic Light Exposure in Pediatric Brain Tumor Survivors
- Texas Children's Hospital, Houston
Ap rekrite
Laj 10 a 18 · Tout sèks · Mizajou Sep 18, 2025 · NCT05340881A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
- MD Anderson, Houston
- NEXT Oncology, San Antonio
Ap rekriteFaz 1/2
Laj 18 a 89 · Tout sèks · Mizajou Aug 19, 2025 · NCT06907043Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.